Paul Dorian


Scientist, Keenan Research Centre for Biomedical Science

Research Programs


Dr. Paul Dorian is the Department Director, Division of Cardiology, University of Toronto and Staff Cardiac Electrophysiologist at St. Michael’s Hospital. He is Professor of Medicine in the Division of Cardiology and in the Division of Clinical Pharmacology at the University of Toronto, and a Staff Scientist at the Li Ka Shing Knowledge Institute.

Dr. Dorian received his medical degree from McGill University in Montreal in 1976. He continued training in Internal Medicine and Cardiology at the University of Toronto, and received certification by the Royal College of Physicians and Surgeons of Canada in Internal Medicine in 1983 and certification in Cardiology in 1984. He completed training in Clinical Pharmacology at the University of Toronto in 1982, and received an MSc in Pharmacology from the University of Toronto in 1982. From 1983 to 1985, he completed a Fellowship in Cardiac Electrophysiology at Stanford University Medical Centre in California.

His research interests include basic science research in advanced cardiac life support and atrial fibrillation, the clinical pharmacology of antiarrhythmic drugs, and clinical research on implanted devices, antiarrhythmic drugs, and quality of life in patients with arrhythmias.

He is the immediate Past-President of the Canadian Heart Rhythm Society, Chairman of the Cardiac Arrest Committee, St. Michael’s Hospital, Co-Principle Investigator on the National Institutes of Health funded Resuscitation Outcomes Consortium, and serves on the steering committee of multiple multicenter clinical trials in arrhythmia care. He is the Chair of the Canadian Cardiovascular Society Quality Committee.

He has published over 350 peer reviewed papers and is Associate Editor of the textbook Electrophysiological Disorders of the Heart.

Please note: Dr. Dorian is not taking any summer students in 2017.

Recent Publications

  1. Bhatia, RS, Bouck, Z, Ivers, NM, Mecredy, G, Singh, J, Pendrith, C et al.. Electrocardiograms in Low-Risk Patients Undergoing An Annual Health Examination. JAMA Intern Med. 2017; :. doi: 10.1001/jamainternmed.2017.2649. PubMed PMID:28692719 .
  2. Silberberg, A, Tan, MK, Yan, AT, Angaran, P, Dorian, P, Bucci, C et al.. Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation: From the Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation (CONNECT AF). Am. J. Cardiol. 2017; :. doi: 10.1016/j.amjcard.2017.05.027. PubMed PMID:28666577 .
  3. Allan, KS, Morrison, LJ, Pinter, A, Tu, JV, Dorian, P, Rescu Epistry Investigators et al.. "Presumed cardiac" arrest in children and young adults: A misnomer?. Resuscitation. 2017;117 :73-79. doi: 10.1016/j.resuscitation.2017.06.003. PubMed PMID:28602695 .
  4. Harel, Z, Chertow, GM, Shah, PS, Harel, S, Dorian, P, Yan, AT et al.. Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. Can J Cardiol. 2017;33 (6):737-746. doi: 10.1016/j.cjca.2017.02.004. PubMed PMID:28545622 .
  5. Jimenez-Juan, L, Karur, GR, Connelly, KA, Deva, D, Yan, RT, Wald, RM et al.. Relationship between right and left ventricular function in candidates for implantable cardioverter defibrillator with low left ventricular ejection fraction. J Arrhythm. 2017;33 (2):134-138. doi: 10.1016/j.joa.2016.07.005. PubMed PMID:28416981 PubMed Central PMC5388044.
  6. Cowper, PA, Sheng, S, Lopes, RD, Anstrom, KJ, Stafford, JA, Davidson-Ray, L et al.. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2017;2 (5):525-534. doi: 10.1001/jamacardio.2017.0065. PubMed PMID:28355434 .
  7. Dorian, P, Ha, AC. Cardioversion for Atrial Fibrillation Improves Quality of Life: It's Obvious (or Isn't It?). Can J Cardiol. 2017;33 (4):425-427. doi: 10.1016/j.cjca.2017.01.013. PubMed PMID:28343603 .
  8. Nosrati, R, Lin, S, Ramadeen, A, Monjazebi, D, Dorian, P, Toronov, V et al.. Cerebral Hemodynamics and Metabolism During Cardiac Arrest and Cardiopulmonary Resuscitation Using Hyperspectral Near Infrared Spectroscopy. Circ. J. 2017;81 (6):879-887. doi: 10.1253/circj.CJ-16-1225. PubMed PMID:28302943 .
  9. Sapp, JL, Parkash, R, Wells, GA, Yetisir, E, Gardner, MJ, Healey, JS et al.. Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial. Circ Arrhythm Electrophysiol. 2017;10 (3):. doi: 10.1161/CIRCEP.116.004875. PubMed PMID:28292754 .
  10. Robinson, VM, Bharucha, DB, Mahaffey, KW, Dorian, P, Kowey, PR, SHIELD-2 Investigators et al.. Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial. Am. Heart J. 2017;185 :43-51. doi: 10.1016/j.ahj.2016.10.025. PubMed PMID:28267474 .
Search PubMed

Affiliations & Other Activities

  • Staff Cardiac Electrophysiologist, St. Michael’s Hospital
  • Professor, Medicine and Cardiology, St. Michael’s Hospital, University of Toronto
  • Director, Division of Cardiology, University of Toronto